Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

Chest

Volumn 142, Issue 3, 2012, Pages 718-724

  Flume, Patrick A ^a   Liou, Theodore G ^b   Borowitz, Drucy S ^c   Li, Haihong ^d   Yen, Karl ^d   Ordoñez, Claudia L ^d   Geller, David E ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

^e NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IVACAFTOR; PHENYLALANINE; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; ASTHENIA; BRONCHUS SECRETION; CFTR GENE; CHILD; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DENTAL CARIES; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GENE DELETION; HEMOPTYSIS; HOMOZYGOTE; HUMAN; HYPOXIA; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NOSE CONGESTION; NOSE POLYP; OPEN STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 84865853894     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2672     Document Type: Article

References (18)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992-2001. (Pubitemid 40638370)
2. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet. 2003;361(9370):1671- 1676.
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-1080. (Pubitemid 19231815)
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073. (Pubitemid 19231814)
5. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059- 1065. (Pubitemid 19231813)
6. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report to the Center Directors. Bethesda, MD:2010.
7. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358(6389):761-764.
8. Kartner N, Augustinas O, Jensen TJ, Naismith AL, Riordan JR. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet. 1992;1(5):321-327.
9. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508- CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 2006;290(6):L1117-L1130. (Pubitemid 43830856)
10. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825-18830.
11. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606. (Pubitemid 34556480)
12. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003.
13. Bronsveld I, Mekus F, Bijman J, et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest. 2001;108(11):1705-1715. (Pubitemid 33144880)
14. Veeze HJ, Halley DJ, Bijman J, de Jongste JC, de Jonge HR, Sinaasappel M. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest. 1994;93(2):461-466.
15. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Devel opment and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347-2354. (Pubitemid 41507578)
16. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
17. Rose JB, Ellis L, John B, et al. Does the Macroduct collection system reliably define sweat chloride concentration in subjects with intermediate results? Clin Biochem. 2009;42(12):1260-1264.
18. Fuchs HJ, Borowitz DS, Christiansen DH, et al The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642. (Pubitemid 24276863)